reporting season

Over the last few years, Paradigm Biopharmaceuticals (PAR) has grown from an unknown small cap to a $600 million dollar drug developer. With trials and approvals...

Artificial intelligence giant Appen notched up a miss on Thursday. But are the company’s lacklustre EBITDA results just a consequence of an unpredictable market and a...

If there was such a thing as a fairy tale in an investment context, the ASX’s tech darling Afterpay (ASX:APT) would no doubt be a worthy poster child. For investors...

The investment landscape remains particularly uncertain at the moment. We are observing a wide range of economic forecasts and a large degree of earnings uncertainty. ...

Throughout the time of COVID-19, healthcare stocks have been catching the eyes of investors. You would have thought that a company that specialises in infection...

High iron ore prices and supply disruptions in Brazil have many forecasting lower profits for Fortescue in FY21, but Stephane Andre from Alphinity Investment...

Iron ore prices should hold above $100 in the medium term on the back of continued demand from China and stimulus in developed markets, says John Ayoub from Wilson...

Welcome to the FNArena Reporting Season Monitor for the August result season 2020. The Monitor reports ratings and consensus price target changes, along with...

There's a lot for investors to get excited about when it comes to Audinate (ASX:AD8), the leading provider of professional digital audio networking technologies...

EML reported a result that was in line with expectations, however there is quite a bit to unpack given the impacts of COVID-19 and the PFS acquisition on the result. ...